Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
GlobalData on MSN6d
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Zacks.com on MSN5d
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateAmgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
(Image Credits: Pixabay) Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density. The development comes a day after those concerns wiped off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback